JP2023532904A5 - - Google Patents

Info

Publication number
JP2023532904A5
JP2023532904A5 JP2022580769A JP2022580769A JP2023532904A5 JP 2023532904 A5 JP2023532904 A5 JP 2023532904A5 JP 2022580769 A JP2022580769 A JP 2022580769A JP 2022580769 A JP2022580769 A JP 2022580769A JP 2023532904 A5 JP2023532904 A5 JP 2023532904A5
Authority
JP
Japan
Prior art keywords
antigen
binding domain
substitution
domain binds
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022580769A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532904A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/040061 external-priority patent/WO2022006380A2/en
Publication of JP2023532904A publication Critical patent/JP2023532904A/ja
Publication of JP2023532904A5 publication Critical patent/JP2023532904A5/ja
Priority to JP2026032254A priority Critical patent/JP2026094308A/ja
Pending legal-status Critical Current

Links

JP2022580769A 2020-07-02 2021-07-01 修飾il-2ポリペプチドを含むポリペプチド及びその使用 Pending JP2023532904A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026032254A JP2026094308A (ja) 2020-07-02 2026-03-02 修飾il-2ポリペプチドを含むポリペプチド及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063047681P 2020-07-02 2020-07-02
US63/047,681 2020-07-02
PCT/US2021/040061 WO2022006380A2 (en) 2020-07-02 2021-07-01 Polypeptides comprising modified il-2 polypeptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026032254A Division JP2026094308A (ja) 2020-07-02 2026-03-02 修飾il-2ポリペプチドを含むポリペプチド及びその使用

Publications (2)

Publication Number Publication Date
JP2023532904A JP2023532904A (ja) 2023-08-01
JP2023532904A5 true JP2023532904A5 (cg-RX-API-DMAC7.html) 2024-07-03

Family

ID=77127075

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022580769A Pending JP2023532904A (ja) 2020-07-02 2021-07-01 修飾il-2ポリペプチドを含むポリペプチド及びその使用
JP2026032254A Pending JP2026094308A (ja) 2020-07-02 2026-03-02 修飾il-2ポリペプチドを含むポリペプチド及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026032254A Pending JP2026094308A (ja) 2020-07-02 2026-03-02 修飾il-2ポリペプチドを含むポリペプチド及びその使用

Country Status (12)

Country Link
US (1) US20230235005A1 (cg-RX-API-DMAC7.html)
EP (1) EP4175979A2 (cg-RX-API-DMAC7.html)
JP (2) JP2023532904A (cg-RX-API-DMAC7.html)
KR (1) KR20230035076A (cg-RX-API-DMAC7.html)
CN (1) CN116615440A (cg-RX-API-DMAC7.html)
AR (1) AR122863A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021299552A1 (cg-RX-API-DMAC7.html)
CA (1) CA3184618A1 (cg-RX-API-DMAC7.html)
IL (1) IL299542A (cg-RX-API-DMAC7.html)
MX (1) MX2022016532A (cg-RX-API-DMAC7.html)
TW (1) TW202216745A (cg-RX-API-DMAC7.html)
WO (1) WO2022006380A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230112632A (ko) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
WO2022245500A1 (en) 2021-05-19 2022-11-24 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
TW202334193A (zh) * 2022-01-05 2023-09-01 美商英伊布里克斯公司 靶向γδ T細胞之經修飾IL-2多肽及其用途
EP4477673A4 (en) * 2022-02-11 2025-09-03 Jiangsu Hengrui Pharmaceuticals Co Ltd IMMUNOCONJUGATE AND ITS USE
CN119546343A (zh) * 2022-04-27 2025-02-28 亚设生物治疗公司 细胞因子融合蛋白与cd8抗原结合分子的组合
IL317511A (en) 2022-06-16 2025-02-01 Cephalon Llc IL-2 immunoconjugates attenuated by anti-PD-1 antibody and their uses
WO2024008126A1 (en) * 2022-07-06 2024-01-11 Elpiscience (Suzhou) Biopharma, Ltd. Il2 muteins and uses thereof
CN116041539B (zh) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 Il-2突变体免疫缀合物
KR20250143339A (ko) * 2023-02-06 2025-10-01 메르크 파텐트 게엠베하 VHH-기반 NKp46 결합제
EP4770754A1 (en) 2023-08-30 2026-07-08 Xilio Development, Inc. Vhh masked cytokines and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DK1678314T3 (da) 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
KR20070003934A (ko) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
JP6592505B2 (ja) * 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
KR20240115933A (ko) * 2016-05-04 2024-07-26 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
CN110325205B (zh) * 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
AU2019288496B2 (en) * 2018-06-22 2024-11-21 Cugene Inc. Interleukin-2 variants and methods of uses thereof
SG11202005873QA (en) * 2018-09-17 2020-07-29 Gi Innovation Inc Fusion protein comprising il-2 protein and cd80 protein, and use thereof
CN113924311A (zh) * 2019-01-07 2022-01-11 印希比股份有限公司 包含修饰的il-2多肽的多肽及其用途
JP7778571B2 (ja) * 2019-06-05 2025-12-02 アッシャー バイオセラピューティクス, インコーポレイテッド 免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体

Similar Documents

Publication Publication Date Title
JP2022516557A5 (cg-RX-API-DMAC7.html)
JP5851419B2 (ja) ヘテロダイマー結合タンパク質およびその使用
Xu et al. Production of bispecific antibodies in “knobs-into-holes” using a cell-free expression system
Chen et al. Bispecific antibodies in cancer immunotherapy
Choi et al. A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity
KR102629905B1 (ko) 항-pd-l1/항-pd-1 천연 항체 구조-유사 헤테로다이머 이중특이성 항체 및 그의 제조
CN113195530B (zh) 抗体融合蛋白、制备方法及其应用
US20130129723A1 (en) Heterodimer Binding Proteins and Uses Thereof
JP2023548045A5 (cg-RX-API-DMAC7.html)
US20220089722A1 (en) Heterodimeric fusion protein
WO2023051727A1 (zh) 结合cd3的抗体及其用途
CA3043652A1 (en) Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
CN115836084A (zh) 多特异性免疫调节剂
EP4349870A1 (en) Anti-cd3 antibody variant, fusion protein, and application
Brinkmann et al. The making of multispecific immunoglobulins–a clinical perspective
WO2024208777A1 (en) All-in-one agonistic antibodies
RU2021123226A (ru) Полипептиды, содержащие модифицированный полипептид il-2, и их применения
WO2025201240A1 (en) Antibodies targeting cd3, cd28, and pd-l1 and uses thereof
WO2023219121A1 (ja) 抗taa-抗cd3多重特異性抗体
TW202404638A (zh) 抗tspan8-抗cd3雙特異性抗體之與pd-1訊息抑制劑之組合在癌治療的用途
JP2024522078A (ja) 抗gpc3及び抗cd137多重特異性抗体ならびにそれらの使用方法
HK1182402A (zh) 異二聚體結合蛋白及其應用